A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 11,130,000 shares of CMPX stock, worth $20.1 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
11,130,000
Previous 11,130,000 -0.0%
Holding current value
$20.1 Million
Previous $22 Million 49.49%
% of portfolio
0.02%
Previous 0.04%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.2 - $2.29 $1.5 Million - $2.86 Million
1,250,000 Added 12.65%
11,130,000 $22 Million
Q4 2023

Feb 14, 2024

BUY
$1.4 - $1.98 $4.9 Million - $6.93 Million
3,500,000 Added 54.86%
9,880,000 $15.4 Million
Q3 2023

Nov 14, 2023

BUY
$1.87 - $3.25 $243,100 - $422,500
130,000 Added 2.08%
6,380,000 $12.6 Million
Q1 2023

May 15, 2023

BUY
$3.14 - $5.48 $1.49 Million - $2.6 Million
475,200 Added 8.23%
6,250,000 $20.4 Million
Q4 2022

Feb 14, 2023

BUY
$2.55 - $5.41 $2.98 Million - $6.32 Million
1,168,200 Added 25.36%
5,774,800 $29 Million
Q3 2022

Nov 14, 2022

BUY
$1.9 - $3.37 $380,000 - $674,000
200,000 Added 4.54%
4,606,600 $10.5 Million
Q2 2022

Aug 15, 2022

BUY
$1.43 - $3.1 $3.05 Million - $6.6 Million
2,129,600 Added 93.53%
4,406,600 $11.7 Million
Q1 2022

May 16, 2022

BUY
$1.25 - $3.5 $1.1 Million - $3.07 Million
877,000 Added 62.64%
2,277,000 $3.12 Million
Q4 2021

Feb 14, 2022

BUY
$2.88 - $3.98 $4.03 Million - $5.57 Million
1,400,000 New
1,400,000 $4.44 Million

Others Institutions Holding CMPX

About Compass Therapeutics, Inc.


  • Ticker CMPX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 101,285,000
  • Market Cap $183M
  • Description
  • Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...
More about CMPX
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.